Sign in or create an account to add this stock to your watchlist.
About Xenon Pharmaceuticals (NASDAQ:XENE)
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It clinical development pipeline includes XEN1101, a Kv7 potassium channel opener for the treatment of epilepsy comprising treatment-resistant adult and pediatric focal seizures, rare and pediatric forms of epilepsy, and other neurological disorders; and XEN901, a selective Nav1.6 sodium channel inhibitor for the treatment of epilepsy. The company also develops GDC-0310 that completed Phase I clinical trials for the treatment of pain; and XEN007, a central nervous system (CNS)-acting calcium channel blocker that directly modulates Cav2.1, which is a critical calcium channel implicated in the pathophysiology of hemiplegic migraine, a rare and debilitating neurological disorder. Xenon Pharmaceuticals Inc. has collaboration agreements with Genentech, Inc. and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XENE
CUSIPN/A
Phone604-484-3300
Debt
Debt-to-Equity Ratio0.82
Current Ratio9.70
Quick Ratio9.70
Price-To-Earnings
Trailing P/E Ratio-3.20
Forward P/E Ratio-3.72
P/E GrowthN/A
Sales & Book Value
Annual Sales$310,000.00
Price / Sales251.40
Cash FlowN/A
Price / CashN/A
Book Value$0.47 per share
Price / Book11.70
Profitability
EPS (Most Recent Fiscal Year)($1.72)
Net Income$-30,700,000.00
Net Margins-9,872.67%
Return on Equity-79.04%
Return on Assets-58.43%
Miscellaneous
Employees81
Outstanding Shares14,170,000
Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions
What is Xenon Pharmaceuticals' stock symbol?
Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."
How were Xenon Pharmaceuticals' earnings last quarter?
Xenon Pharmaceuticals Inc (NASDAQ:XENE) announced its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.48) by $0.27. Xenon Pharmaceuticals had a negative net margin of 9,872.67% and a negative return on equity of 79.04%. View Xenon Pharmaceuticals' Earnings History.
When is Xenon Pharmaceuticals' next earnings date?
What price target have analysts set for XENE?
3 analysts have issued twelve-month price targets for Xenon Pharmaceuticals' stock. Their predictions range from $5.00 to $9.00. On average, they anticipate Xenon Pharmaceuticals' stock price to reach $6.6667 in the next year. View Analyst Ratings for Xenon Pharmaceuticals.
Who are some of Xenon Pharmaceuticals' key competitors?
Some companies that are related to Xenon Pharmaceuticals include Sienna Biopharmaceuticals (SNNA), BioSpecifics Technologies (BSTC), DURECT (DRRX), Verastem (VSTM), Aquinox Pharmaceuticals (AQXP), Catalyst Biosciences (CBIO), Corium International (CORI), Biofrontera (BFRA), Kadmon (KDMN), Tyme Technologies (TYME), Celyad (CYAD), AVEO Pharmaceuticals (AVEO), CTI BioPharma (CTIC), Cue Biopharma (CUE) and Kindred Biosciences (KIN).
Who are Xenon Pharmaceuticals' key executives?
Xenon Pharmaceuticals' management team includes the folowing people:
- Dr. Simon N. Pimstone, CEO & Director (Age 50)
- Mr. Ian C. Mortimer, Pres, CFO, COO & Company Sec. (Age 42)
- Mr. Robin P. Sherrington, Exec. VP of Bus. & Corp. Devel. (Age 57)
- Dr. Y. Paul Goldberg, Sr. VP of Clinical Devel. (Age 58)
- Dr. James R. Empfield Ph.D., Sr. VP of Drug Discovery of Xenon Pharmaceuticals USA Inc (Age 57)
Has Xenon Pharmaceuticals been receiving favorable news coverage?
News coverage about XENE stock has trended somewhat positive on Friday, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Xenon Pharmaceuticals earned a media sentiment score of 0.09 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 45.20 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Xenon Pharmaceuticals' major shareholders?
Xenon Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BVF Inc. IL (5.09%), Nexthera Capital LP (2.68%), Knott David M (0.81%) and Sabby Management LLC (0.47%). Company insiders that own Xenon Pharmaceuticals stock include Bvf Partners L P/Il, Frank A Holler, Gary Patou, Ian Mortimer, James R Empfield, Michael R Hayden, Mohammad Azab, Raymond Winquist, Richard H Scheller, Simon N Pimstone, Steven Gannon and Value Fund L P Biotechnology. View Institutional Ownership Trends for Xenon Pharmaceuticals.
Which institutional investors are selling Xenon Pharmaceuticals stock?
Which institutional investors are buying Xenon Pharmaceuticals stock?
XENE stock was acquired by a variety of institutional investors in the last quarter, including Nexthera Capital LP and Knott David M. Company insiders that have bought Xenon Pharmaceuticals stock in the last two years include Bvf Partners L P/Il, Gary Patou, Ian Mortimer, James R Empfield, Michael R Hayden, Mohammad Azab, Raymond Winquist, Richard H Scheller, Simon N Pimstone, Steven Gannon and Value Fund L P Biotechnology. View Insider Buying and Selling for Xenon Pharmaceuticals.
How do I buy shares of Xenon Pharmaceuticals?
Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Xenon Pharmaceuticals' stock price today?
One share of XENE stock can currently be purchased for approximately $5.45.
How big of a company is Xenon Pharmaceuticals?
Xenon Pharmaceuticals has a market capitalization of $79.36 million and generates $310,000.00 in revenue each year. The biopharmaceutical company earns $-30,700,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Xenon Pharmaceuticals employs 81 workers across the globe.
How can I contact Xenon Pharmaceuticals?
Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]
MarketBeat Community Rating for Xenon Pharmaceuticals (XENE)
MarketBeat's community ratings are surveys of what our community members think about Xenon Pharmaceuticals and other stocks. Vote "Outperform" if you believe XENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENE will underperform the S&P 500 over the long term. You may vote once every thirty days.
Xenon Pharmaceuticals (NASDAQ:XENE) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Xenon Pharmaceuticals in the last 12 months. Their average twelve-month price target is $6.6667, suggesting that the stock has a possible upside of 21.21%. The high price target for XENE is $9.00 and the low price target for XENE is $5.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $6.6667 | $6.6667 | $5.00 | $8.1667 |
| Price Target Upside: | 21.21% upside | 36.05% upside | 66.67% upside | 172.22% upside |
Xenon Pharmaceuticals (NASDAQ:XENE) Consensus Price Target History
Xenon Pharmaceuticals (NASDAQ:XENE) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
Xenon Pharmaceuticals (NASDAQ:XENE) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Xenon Pharmaceuticals (NASDAQ XENE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 14.13%
Institutional Ownership Percentage: 44.82%
Xenon Pharmaceuticals (NASDAQ XENE) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/15/2017 | Mohammad Azab | Director | Buy | 15,000 | $2.22 | $33,300.00 | |  |
| 9/22/2017 | Mohammad Azab | Director | Buy | 10,000 | $2.95 | $29,500.00 | 21,210 | |
| 8/18/2017 | Mohammad Azab | Director | Buy | 6,335 | $2.90 | $18,371.50 | 12,898 | |
| 8/18/2017 | Raymond Winquist | Insider | Buy | 1,000 | $3.00 | $3,000.00 | 1,000 | |
| 8/15/2017 | Bvf Partners L P/Il | Major Shareholder | Buy | 18,858 | $2.41 | $45,447.78 | | |
| 8/15/2017 | James R Empfield | SVP | Buy | 10,000 | $2.48 | $24,800.00 | 10,000 | |
| 8/15/2017 | Value Fund L P Biotechnology | Insider | Buy | 60,202 | $2.61 | $157,127.22 | | |
| 8/14/2017 | Bvf Partners L P/Il | Major Shareholder | Buy | 41,344 | $2.70 | $111,628.80 | | |
| 8/14/2017 | Michael R Hayden | Director | Buy | 15,000 | $2.75 | $41,250.00 | 161,187 | |
| 8/11/2017 | Steven Gannon | Director | Buy | 15,000 | $2.82 | $42,300.00 | 15,000 | |
| 8/10/2017 | Ian Mortimer | CFO | Buy | 15,000 | $2.88 | $43,200.00 | 6,000 | |
| 8/10/2017 | Richard H Scheller | Director | Buy | 7,000 | $2.85 | $19,950.00 | 7,000 | |
| 8/10/2017 | Simon N Pimstone | CEO | Buy | 6,000 | $2.90 | $17,400.00 | 217,847 | |
| 8/8/2017 | Gary Patou | Director | Buy | 5,000 | $3.00 | $15,000.00 | 12,028 | |
| 6/27/2017 | Value Fund L P Biotechnology | Insider | Buy | 85,461 | $4.00 | $341,844.00 | | |
| 6/22/2017 | Value Fund L P Biotechnology | Insider | Buy | 20,411 | $4.00 | $81,644.00 | | |
| 6/19/2017 | Value Fund L P Biotechnology | Insider | Buy | 26,408 | $3.84 | $101,406.72 | | |
| 6/7/2017 | Value Fund L P Biotechnology | Insider | Buy | 358,698 | $3.81 | $1,366,639.38 | | |
| 12/15/2016 | Frank A Holler | Director | Sell | 30,000 | $7.85 | $235,500.00 | 115,869 | |
| 8/19/2016 | Frank A Holler | Director | Sell | 11,938 | $7.65 | $91,325.70 | 145,869 | |
| 8/18/2016 | Frank A Holler | Director | Sell | 18,062 | $7.93 | $143,231.66 | 169,006 | |
| 6/24/2016 | Ian Mortimer | CFO | Buy | 5,300 | $6.22 | $32,966.00 | 1,000 | |
| 9/24/2015 | Y. Paul Goldberg | VP | Sell | 22,149 | $8.88 | $196,683.12 | 6,000 | |
(Data available from 1/1/2013 forward)
Xenon Pharmaceuticals (NASDAQ XENE) News Headlines
| Source: |
|
Xenon Pharmaceuticals (NASDAQ:XENE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Xenon Pharmaceuticals (NASDAQ:XENE) Income Statement, Balance Sheet and Cash Flow Statement
Xenon Pharmaceuticals (NASDAQ XENE) Stock Chart for Friday, May, 25, 2018
Loading chart…
